Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Neoplasms
Interventions: OTHER: Aromatase inhibitors
Sponsor: Pfizer